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ABSTRACT: Quantum mechanics and molecular dynamics were used to study the inclusion of 
neutral and deprotonated aspirin into the –cyclodextrin (–CD) cavity. The molecular dynamic 
simulation allows following the time dependent behavior of the formation of the inclusion 
complex. For both complexes, we find a reasonable and a realistic pattern of the complexation. 
The calculations show a single pathway consisting of an irreversible process leading to the 
complexation of aspirin. Whereas, for deprotonated aspirin it has been observed a reversible 
complexation, in which one way leads to the binding form, and the reverse way to the unbinding 
form. Throughout the simulation, the penetration of aspirin (ASA) or deprotonated aspirin 
(ASA–) inside the cavity occurs only with a phenyl ring entering first through the wider or 
narrower rim. The Molecular Dynamics (MD) study results in a favorable inclusion process for 
aspirin and an unfavorable one for the deprotonated aspirin. A few remarkable conformations of 
the neutral complex were examined in particular detail. The lowest energy minimum structures 
of the complexes are obtained with B3LYP/cc-pvdz calculations. The neutral aspirin complex, 
wherein the guest is deeply embedded inside the cavity, is found more favorable than the 
deprotonated one, which is partially included. These geometries are well characterized by UV 
and IR calculation spectra, and confirm the consistency of both the MD results and the 
experimental observations. The intermolecular interactions between the aspirin and –CD are 
modeled by the NBO and AIM methods. Finally, it turned out, that the most important driving 
forces of the complexation are, the hydrogen bonds, and the hydrophobic/hydrophilic 
interactions. 
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1- INTRODUCTION 
An inclusion complex – a combination of two or more species - is based on a non-covalent 
interactions between the host and guest molecules and their stability depends on the size and 
complementary forms of host and guest molecules. Additionnaly, the external medium and 
environmental conditions can also play a role [1, 4].  
–cyclodextrin (–CD) is a cyclic oligosaccharide derived by enzymatic hydrolysis of 
common starch. Due to its peculiar chemical structure, constituted of an external hydrophilic 
surface and a hydrophobic cavity, –CD  can form inclusion complexes with a variety of organic 
molecules, thereby improving some of their properties, such as solubility, stability and bio-
availability [5-7]. 
The main forces involved in the complexation process are electrostatics, van der Waals, 
hydrophobic interactions, hydrogen bonding and charge transfer interactions [8-10]. The 
complexation process in solution comprises several steps, which we briefly summarize here: at 
first, as the guest molecule approaches the -CD cavity, it is released from the hydration layer 
which surrounded it, and conjointly the water molecules which are inside the cavity are released 
outside. Then, the guest molecule penetrates inside the -CD cavity giving a chemical complex 
stabilized only by non-covalent interactions [8].  
If the guest molecule finds a great stability inside the cavity, it will remain there for a long 
time, and the process can be considered as an irreversible binding process. Otherwise, without 
large stabilizing interactions with the host molecule inside the cavity, it will be released and 
water molecules would return in the cavity. However, the guest molecule can return inside the 
cavity so the process is considered as a reversible binding process which can occur repeatedly 
[11].  
Several factors may influence the inclusion complex formation, such as the type of CD, cavity 
size, pH and ionization state, temperature and method of preparation [12]. For instance, when the 
guest molecule is negatively charged it reduces its complexation ability compared to the neutral 
form. This is due to the fact that the negative charge reduces the hydrophobicity of the guest 
molecule and impedes its penetration inside the hydrophobic cavity [13].  
The molecular encapsulation process has constituted a major area of expertise and 
investigation within the framework of supramolecular chemistry. It became the subject of intense 
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experimental and theoretical studies because the detailed knowledge of the dynamics of 
complexation constitutes the basis of its use as a drug carrier [12-19]. 
Acetylsalicylic acid (ASA), also known by the trade name aspirin, is one of the most known, 
used and popular drugs. It belongs to a group of medication called non-steroidal anti-
inflammatory drug (NSAIDs); it is often used to treat pain [18], fever [19], inflammation [20], to 
help prevent heart attacks [21], blood clot formation [22], and in a certain type of cancer, as 
colorectal or pancreatic cancer [23, 24].  
The spontaneous hydrolysis of aspirin vary markedly with pH. At pH below 2.5 aspirin is in its 
neutral form, whereas, at higher pH it becomes increasingly deprotonated.  Its rate of absorption 
in the stomach, which has a pH of 1.5 to 3.5 depends on its form. Thus, the majority of the 
biological activities, attributed to the neutral form is due to its lipophilic nature, which facilitates 
its absorption through the stomach wall, and its passing into the bloodstream [25, 26]. 
In many cases their use at higher doses can generate bad side effects, notably gastric irritation, 
gastrointestinal ulcers, hematemesis, tinnitus and stomach bleeding [27, 28]. These 
inconveniences are due, in particular, to its low solubility in water estimated to 1 g/300 ml [29], 
caused by its rapid decomposition in two acids, salicylic and acetic [30].  
Several methods are used to overcome these inconveniences such as its use as a pro drug or 
microencapsulation. The microencapsulation system, also named inclusion complex, is 
constituted of two molecules forming a single entity in which the molecule called "guest" is 
trapped in the cavity of another one, called "host"; and the system is stabilized only by non-
covalent interactions [31, 32].  
The application of the microencapsulation technique, allows improving the apparent solubility 
of poorly soluble molecules, protecting the fragile ones from unfavorable conditions and 
enhancing its therapeutic properties, such as its use as a drug delivery system (DDS) [33–41].  
Many authors have studied the complexation process of aspirin with –cyclodextrin using 
various techniques such as X-ray (RX) [42, 43], spectroscopic methods [44–48], ultrasonic 
relaxation [49], and isothermal calorimetric titration [27]. These studies led to the following 
conclusions: (i) the inclusion is deep with neutral aspirin (ASA) and partial with the 
deprotonated form (ASA
–
); (ii) the phenyl moiety of neutral aspirin is localized inside the cavity, 
whereas, with the deprotonated form it is largely outside; (iii) hydrophobic interactions and 
hydrogen bonds play the major role in the complexation.  
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However, there are still outstanding issues that deserves further studies, such as the evolution 
of complexation process and the effect of the inclusion on ultraviolet (UV) and infrared (IR) 
spectra. 
Computational chemistry methods can give appropriate answers because they have already had 
a great success in solving several problems related to the geometry, the physical chemistry, and 
the driving forces of the complexation [50–54]. 
The number of published papers in the past decade on this topic has widely increased, showing 
the evidence of a passion, attesting the mastery and the growing knowledge on the subject [55-
57]. Furthermore, while the pH is of primary importance for its biological effect, to the best of 
our knowledge, there are no reports in the literature on the evolution of the complexation of –
CD with neutral vs deprotonated aspirin. This also motivated the present study.  
For this purpose, we describe, in this article, a computational study on the complexation 
process between neutral/deprotonated aspirin and –CD using molecular dynamics and quantum 
mechanics. Then, the spectral calculations with B3LYP/cc-pvtz were used to provide a clear 
picture and to gain significant knowledge on these complexes. Finally, we shall focus our 
attention on the hydrogen bonds, one of the main driving forces of the complexation by using 
both natural bond orbital (NBO) and atoms  in molecules (AIM) methods. 
 
2- METHODS 
The initial geometry of the system is prepared using the graphical interface of the 
ChemBioOffice software. The initial structure of –CD was built with the help of 
ChemBioOffice (version 10, Cambridge software) [58], and the geometry of aspirin was 
extracted from a PubChem Compound Database [59] (Figure 1). Two possible orientations were 
considered. When complexation occurs by the wider side is called “orientation A” and when it 
occurs by the narrower side is called “orientation B”.  
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Figure 1. Aspirin and –CD  molecular structures 
 
Two methodological approaches were used to describe the inclusion process, automatic for 
molecular dynamics and manual for quantum mechanics. 
2.1 Molecular dynamics 
First, –CD is fixed in the center of XYZ coordinate system. Then, neutral/deprotonated aspirin 
is placed on the X-coordinate axes at a distance equal to 14 Å from the center of –CD (Figure 1, 
2).  
 
Figure 2 The initial geometry of the aspirin and –CD molecules in the water box at the 
beginning of the simulation. 
The force field parameters for both molecules were generated using the automated topology 
builder (ATB) [60] in the framework of GROMOS96 54A7 force field [61] [see supplementary 
materials]. 
All simulations were carried out using the GROMACS package version 5.2.1 into an identical 
box containing 2638 water molecules represented by a simple point charge (SPC) model [62, 
x
-7Å +7Å
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63]. The simulations were performed in the isobaric-isothermal ensemble (NPT) with a constant 
pressure of 1 bar and a temperature of 298 K controlled by the Berendsen thermostat. The 
electrostatic interactions were treated by the particle mesh Ewald (PME) method with a cutoff 
distance of 1.2 nm; and the van der Waals interactions were modeled using a cutoff of 1.4 nm. 
The whole system was relaxed using the steepest descent algorithm. The position of the guest 
molecule is obviously altered after the equilibration steps. The classical Newton’s equations of 
motion were integrated using the Leap-Frog algorithm and the Berendsen weak-coupling 
method. All simulations were carried out for 1000 ns, which is long enough for the system to 
reach equilibrium. The trajectory coordinates were recorded every 500 steps with a time step of 1 
fs.  
2.2 Quantum mechanical calculations 
All quantum chemistry calculations were carried out using the Gaussian 09 package [64]. To 
define the aspirin:–CD inclusion complex, the glycosidic oxygen atoms of –CD were placed 
onto the YZ plane, the center of –CD being defined as the origin of the coordinate system. The 
relative position between –CD and Aspirin is measured by the X coordinate of the center of the 
aromatic ring of Aspirin. Aspirin was initially located on an X-coordinate equal to 7 Å and was 
moved into the –CD cavity along the X axis to – 7 Å with a 1 Å step (figure 2). The generated 
structures at each step were optimized with the PM3 semi empirical method, allowing them to 
change from the initial conformations keeping the displacement of the center of  the aromatic 
ring and the –CD.  
 
Then, the complexation energy of all structures was calculated by using the following 
expression: 
∆Ecomplexation= Ecomplex- (Efree aspirin + Efree –cyclodextrin )                     Eq.1 
 Ecomplex is the heat of the formation of the complex, Efree aspirin and Efree cyclodextrin are the 
energies of aspirin and –cyclodextrin molecules in their free state. The more negative is the 
complexation energy, the more thermodynamically favorable is the inclusion complex.  
The two lowest  energy minimum structures of the neutral ASA:–CD and the deprotonated 
ASA
–
:–CD complexes were optimized with the B3LYP/cc-pvdz method [65–69]. 
 
 
 
8 
 
2.3 NBO and AIM analysis 
The stabilization energy E
(2)
 related to the delocalization trend of electrons from a donor to 
acceptor orbitals, is calculated with the NBO method [70]. A large stabilization energy E
(2)
  from 
the LP(Y) lone pair of the proton acceptor to the * (X-H) anti-bonding orbital of proton donor 
is generally indicative of an X-H
…
Y hydrogen bond [71-74].  
Finally, by means of AIM2000 software [75], a topological analysis of electron density with 
Bader’s theory of atoms in molecules (QTAIM) [76-77] is applied on the free 
neutral/deprotonated aspirin (ASA/ASA
–
) and their most favorable complex obtained with 
B3LYP/cc-pvdz method. The wave functions required for this analysis were generated after 
performing a single point calculation at the same level of theory. 
2.4 IR and UV spectra  
The infrared spectra of the neutral/deprotonated (ASA / ASA
–
) free aspirin, free –CD and 
their inclusion complex were calculated at the B3LYP/cc-pvdz level using CPCM model with 
acetonitrile as a solvent. 
Time-dependent density functional theory (TD-DFT) is used to characterize the vertical 
excitation (reference) of all compounds. Thus, from the fundamental geometry of a complex, we 
modelled its absorption spectrum by the analysis of the linear response of the ground state 
density to a time-dependent perturbation (TD-DFT calculations). We simulate the 
photoexcitation and we analyze the set of electronic transitions that results. This calculation 
gives access to the energy necessary to drive each transition and to the associated oscillator force 
when it corresponds to an allowed transition (here we refer to the spectroscopic selection rules). 
The intensity of these transitions is thus obtained, and it is then possible to plot the absorption 
spectra. 
Finally, the UV-vis spectra of free neutral/deprotonated (ASA/ASA
–
) free –CD  and their 
inclusion complex were calculated at the B3LYP/cc-pvdz level using CPCM model with ethanol 
as a solvent.  
 
3- Results and discussions 
3.1 Molecular dynamics 
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Three independent molecular dynamics simulations of 1000 ns were performed to describe the 
inclusion process of neutral/deprotonated (ASA/ASA
–
) aspirin with –CD at the molecular level. 
The simulations with the neutral aspirin are reported in figure 3, with the labels S1, S2, S3 and 
those with the deprotonated aspirin are in figure 6 (S'1, S'2, S'3).  
3.1.1. The inclusion process of aspirin with –CD  
Throughout the simulation, the inclusion process is described through the analysis of the 
variation of the distances between the two centroïds of mass of aspirin and –CD (Figure 3). In 
all three simulations it was observed that the penetrations and exits of aspirin in and out of the 
cavity can occur. As it can be seen in Figure 3, three interesting facts are emerging from the three 
simulations: (i) a rapid penetration of aspirin, which can last only a few ns, followed by a long 
stay inside the cavity; it remains there deeply embedded until the end of the simulation; except of 
the S’2 simulation where around 400 ps aspirin briefly leaves the cavity and returns rapidly 
inside. (ii) also, there are some regions where there are more fluctuations, indicating that aspirin 
moves in these regions freely inside the cavity, exceeding sometimes the limits of the cavity with 
respect to the steps. (iii) changes of the aspirin orientation inside the –CD cavity occur during 
the simulations, from A to B or the reverse, these changes of orientation are made via a few 
unbound forms (Figure 4).  
 
 
 
 
10 
Figure 3. The plot of the variation of the distance between the two 
centroïds of mass of aspirin and –CD during the three simulations.  
 
 
Figure 4. Snapshots showing the unbound states at 960, 113 and 594 ns, of the neutral complex 
extracted from S’1 simulation. 
From these simulations, four key points are highlighted: (i) mostly the complexation process is 
irreversible (ie, once aspirin penetrates into the cavity, it is no longer available in the medium); 
(ii) aspirin can penetrated by the two entrances; (iii) the inclusion complex is favorable in 
aqueous medium because aspirin spent much more time inside the cavity, 982 (S1), 988 (S2) and 
997 (S3) ns than the outside; (iv) the orientation A is more favorable than the B one, because the 
lifetime of the orientation A is larger than that of orientation B: the orientation A lasts 814 (S1), 
705 (S2) and 846 (S3) ns while B lasts 167 (S1), 283 (S2) and 150 (S3) ns. In Figure 5 are 
displayed the averaged geometries of the ASA:–CD complex in the A and B orientation. In the 
A orientation aspirin is deeply embedded inside the cavity, whereas in the orientation B only the 
phenyl ring is included and the functional groups stay in secondary periphery establishing 
hydrogen bonds with –CD. 
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Figure  5. Averages geometries of the ASA:–CD  complex, (a) orientation A (b) orientation B  
 
3.1.2 The inclusion process of deprotonated aspirin with –CD  
The simulations are labelled S'1, S'2, S'3, and they are shown on Figure 6. Throughout all three 
simulations it was observed, that the phenyl group penetrates first through the wider or narrower 
side with equal proportions. The penetration of deprotonated aspirin is incomplete : only the 
phenyl group enters the –CD cavity, whereas the acetyl and carboxylate groups remain outside. 
As can be seen from Figure 6, the variation of the distance between the center of mass of 
deprotonated aspirin and –cyclodextrin is very similar from one simulation to another: S'1 
ressembles S'2 and S'3 is alike. 
In each simulation, it was observed multiple entrances and exits of deprotonated aspirin of the 
cyclodextrin cavity. At each time, the guest molecule remains only a small moment inside the 
cavity with the exception of the periods [300-450] for S'1, [200-310] for S'2 and [700-790] ns for 
S'3 where it passes more than 100 ns inside the cavity. 
Overall, these three simulations are not in favor of an inclusion process because the guest 
molecule spent more time outside the cyclodextrin cavity, and moves freely in the aqueous 
medium. For the S'1, S'2 and S'3 simulations, this occurs 63, 52 and 67% of the time of 
simulation, respectively. Moreover, even when within the cavity the guest molecule, is 
constantly moving along the axis of the cavity and adopts a fairly large number of 
conformations, indicating its instability inside. 
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Figure 6. The variation of the distance between the mass centers of deprotonated aspirin and -
CD during all the three simulations.  
From these simulations, three key points are highlighted: (i) the complexation process is 
reversible (ie. the guest molecule enter and exit the cavity several times) (ii) deprotonated aspirin 
penetrates inside the cavity through both the wider or the narrower rim; (iii) the inclusion 
complex is unfavorable in aqueous medium because deprotonated aspirin spends more time 
outside the cavity. 
  
3.2. Quantum mechanics 
3.2.1 Complexation energies and the structures of the inclusion complexes 
 
Negative values of the complexation energies are synonymous of a favorable process because 
the more negative is the complexation energy, the more thermodynamically favorable is the 
inclusion complex. Thus, the complexation energy of the lowest energy minimum structure is 
found equal to -3.0 to –5.7 kcal.mol
-1
 for the neutral and deprotonated complexes, respectively.  
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Figure  7. Complexation energy of the neutral ASA:–CD complex along the z axis.  
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Figure  8. Complexation energy of ASA
-
:–CD complex along the z axis. 
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Figure 9 Structures of the B3LYP/cc-pvdz energy minimum obtained for the inclusion 
complexes. (a),(c)  deprotonated form (b), (d) neutral form.  
In Figure 9 are displayed the geometries of the two inclusion complexes. The lowest energy 
minimum of the ASA: –CD was localized at 0 Å and that of ASA
-
:–CD at -2.5 Å (Figure 7 
and 8). It shows clearly that the phenyl group is deeply embedded inside the cavity for the 
neutral complex, whereas in the deprotonated form it remains outside. The acetyl and carboxylic, 
of the neutral complex, remain on the narrow rim, where they establish hydrogen bonds with the 
primary hydroxyls of the –CD. However, in the deprotonated complex, the acetyl group is 
located inside the cavity, leaving the carboxylate group on the wide rim establishing three 
hydrogen bonds with the secondary hydroxyls of the –CD.  
This is in agreement with the experimental results which stipulate that deprotonated ASA- 
does not form complex with –CD and neutral ASA form an inclusion complex with establishing 
several hydrogen  bonds with –CD. 
In the following, we will focus only on the lowest energy minimum structures displayed in 
Figure 9.  
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3.2.2 Hydrogen bonding and population analysis 
The strength of hydrogen bonds and their geometrical parameters (distance and angle) are 
closely correlated.[ref] The angle between the atoms involved is linear (> 175°), and the shorter 
the distance (< 2 Å) the stronger the H-bond. Based on several monographs, the hydrogen bonds 
were classified according to the values of their dissociation energies. Thus, are considered as 
weak hydrogen bonds those with an energy of 1 to 4 kcal mol
-1
, moderate for 4 to 15 kcal mol
-1
, 
and strong for 15 to 40 kcal mol
-1
 [78-81]. Herein, the strength of the hydrogen bonds cannot be 
evaluates as a dissociation energy because the dissociation corresponds to several different 
interactions. Hence we used the E
(2)
 stabilization energy obtained by perturbation within the 
NBO method. These values as well as the geometrical parameters of these hydrogen bonds of 
both complexes are given in Table 1. 
 
Table 1. The stabilization energy E
(2)
 obtained with B3LYP/cc-pvdz of the main hydrogen bond 
interactions and their geometrical parameters of both complexes. The d distance is measured 
between H and Y atoms in the (X-H
…
Y) bond, and the angle between X, H and Y atoms implies 
in the hydrogen bond. 
Complex form d (Å) Angle (°) E
(2)
 (kcal/mol) 
Neutral    
Aspirin acceptor and –CD  proton donor   
Lp O160 *(H129-O47)  1.90 166 5.99 
Lp O148 *(H138-O62) 1.95 166 4.11 
–CD  acceptor and aspirin proton donor   
Lp O55 *(H161-O150) 1.97 146 4.65 
Deprotonated    
Aspirin acceptor and –CD  proton donor   
Lp O157 *(H133-O53) 1.81 167 15.23 
Lp O157 *(H134-O54) 1.74 152 14.56 
Lp O158 *(H139-O63) 1.70 171 11.10 
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Based on, E
(2)
 values and the geometrical parameters, the H-bonds of the neutral complex are 
significantly weaker, than those of the deprotonated complex.  
An inspection of the geometry of the neutral complex (Table 1 and Figure 9) shows that there 
are two hydrogen bonds where –CD plays a proton donor role, and it plays an acceptor role in a 
third one. The first H-bond occurs between O160 of the acetyl group and H129 of the H129-O47 
bond of –CD, and the second between O148 of the carboxylic group and H138 of the H138-
O62 of –CD. The third one occurs between carboxylic hydrogen atom (H161) of the H161-
O150 bond of aspirin and a glycosidic oxygen atom (O55) of –CD. 
In the hydrogen bonds of the deprotonated complex, –CD plays the role of a proton donor, 
and aspirin of an acceptor. The first H-bond occurs between O158 of the carboxylate group and 
H139 of the H139-O63 bond of –CD. However, the oxygen atom O157 of the carboxylate 
group is positioned so that it participates in two H-bonds; the first one with H133 of the H133-
O53 bond, and the second with H134 of the H134-O54 bond. 
3.2.3 Hydrogen bonding and AIM analysis  
The Bader AIM method provides a physical picture of the interaction between proton donor 
and acceptor in hydrogen bonding; it is achieved by exploring the topological parameters of the 
electron density b. Its Laplacian 
2
b defines different types of critical points. 
Several criteria relative to the values of the electron density and its Laplacian reported in the 
literature were used to classify and characterize hydrogen bonds at bond critical points (BCPs). 
Thus, it was mentioned that a hydrogen bonding is detected in the range of 0.002-0.04 and 0.024 
-0.139 for b and 
2
b respectively. Larger values of electron density and of its Laplacian give 
stronger hydrogen bonds [82, 83]. 
 
Table 2. Topological analysis obtained with B3LYP/cc-pvdz of the electron density ρb and 
Laplacian 
2
ρb for the main hydrogen bond interactions of both complexes. 
Complex form Interaction ρb 
2
ρb 
Neutral O47
…
HB1···O160 0.0169 0.0658 
O55
…
HB3···O150 0.0155 0.0584 
O62
…
HB2···O148 0.0122 0.0490 
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Deprotonated O53
…
HB2···O157 0.0337 0.1220 
O54
…
HB1···O157 0.0259 0.0926 
O63
…
HB3···O158 0.0235 0.0889 
 
 
According to the values of b and 
2
b displayed in Table 2, there is a trend towards larger 
values for the deprotonated complex and lower values for the neutral complex. This gives a 
further evidence for the characterization of these hydrogen bonds, which are considered 
moderately strong for the deprotonated complex and moderately weak for the neutral one. These 
results were in line with those obtained using NBO method. 
The molecular graph of the deprotonated/neutral complex displayed in Figure 10, visualizes 
clearly the formation of these H-bonds, with the red points (HBn) over the bond path of the H-
bond interaction.  
 
 
Figure 10. Molecular graph of the main hydrogen bond interactions (the yellow circles shows the 
most important) of (a) the neutral complex (b) the deprotonated complexes.  
3.2.4 The hydrophobic/hydrophilic interactions 
The hydrophobic/hydrophilic interaction is discussed based on the interaction between the 
different moieties of the system. Thus, for the neutral complex, the phenyl group molecule, 
considered as hydrophobic, is located inside the hydrophobic cavity of the –CD. However, both 
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of acetyl and carboxylic groups of aspirin, considered as hydrophilic, are localized on the 
hydrophilic periphery of the –CD, in contact with the water molecules. So, the 
hydrophilic/hydrophobic interactions are favorable to the formation of the neutral complex. 
However, for the deprotonated complex, the acetyl hydrophilic group is localized inside the 
hydrophobic cavity of the –CD, and the hydrophobic phenyl group is localized outside the 
cavity in the aqueous medium. So the hydrophobic/hydrophilic interactions are unfavorable to 
the formation of the deprotonated complex.  
 
3.2.5 Infrared analysis 
As the carbonyl groups of aspirin are involved in several hydrogen bonds with –CD, it seems 
interesting to study the inclusion effect on these vibration frequencies. For this purpose, the 
spectra of the complexes and aspirin under both forms are calculated at B3LYP/cc-pvdz level 
with CH3CN as a solvent. We will focus only on the CO vibration region of the IR spectra of 
aspirin (neutral/deprotonated) and their inclusion complexes. The spectrum of the –CD itself is 
not is not considered due to the absence of the carbonyl stretching bands (C=O). 
3.2.5.2 Neutral complex 
The IR spectrum of aspirin shows a band at 1802 cm
-1
 corresponding to the carbonyl stretching 
band (C=O) of the carboxylic group (Figure 11 (a) , Free ASA). This band is shifted towards 
lower frequency (1744 cm
-1
) in the inclusion complex ( = 58 cm-1) (Figure 11 (a) , ASA:–
CD). Similarly, the carbonyl stretching band (C=O) of the acetyl group of aspirin located at 
1820 cm
-1
, is shifted to 1773 cm
-1
 in the inclusion complex ( = 47 cm-1). As it is the case for 
ASA-, the differences in the observed shifts of the carbonyl stretching band (C=O) can also be 
explained by the involvement of these two carbonyl groups in the hydrogen bonds with the 
hydroxyls of –CD. 
In other words, the differences in the observed shifts of the carbonyl stretching band (C=O) 
in the IR spectroscopy constitute the evidence of the formation of the inclusion complex of both 
forms. Accordingly, IR method can be considered as a suitable technique for the detection of the 
formation of the inclusion complexes.  
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Figure 11. (a) On the left, the computed IR spectra shows the shift of the stretching band of CO 
in the free aspirin and in the ASA:–CD complex. (b) On the right, the computed IR spectra 
shows the shift of the stretching band of CO in the free deprotonated aspirin and in the ASA
-
:–
CD  complex 
 
3.2.5.1 Deprotonated complex 
The spectra are displayed in Figure 11. Two carbonyl stretching bands (C=O) frequencies are 
observed in the IR spectrum of deprotonated aspirin, one located at 1687 cm
-1
 attributed to the 
two carbonyls of the carboxylate group and the second is located at 1809 cm
-1 
attributed to the 
carbonyl of the acetyl group (Figure 11 (b), free ASA
-
). The carbonyl stretching band (C=O) of 
the carboxylate group is considerably shifted to the lower frequencies, located at 1634 cm
-1
 ( 
=  53cm
-1
) (Figure 11 (b), ASA
-
:–CD ).  
This difference is more significant in the CO groups of carboxylate because they are involved 
in three hydrogen bonds, which is not the case of the CO group of acetyl not involved in any H-
bonds.  
3.2.6 UV analysis 
We calculated the ultraviolet-visible spectra of both forms of free aspirin, free –CD and their 
complexes in order to get more quantitative information data on these complexes. 
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TD-DFT calculations were made on neutral and deprotonated aspirin, the –CD and their 
inclusion complex at the B3LYP/ cc-pvdz level in ethanol. The obtained spectra are shown in 
Figure 12. 
 
Figure 12 (a) On the left, computed UV spectra of free neutral aspirin, –CD and the ASA: –
CD complex. (b) On the right, computed UV spectra the deprotonated aspirin, –CD and the 
ASA
-
: –CD complex.  
3.2.6.1 Neutral complex 
The computed UV spectrum of the inclusion complex shows a band with a maximum 
absorption located at 251 nm (Figure 12 (a)). Since there is no absorption band from –CD and 
the maximum absorbance of aspirin is located at 220 nm this leads to consider the existence of a 
new component other than aspirin and –CD. If this band is specific to the formed complex, it 
should be made up of transitions between aspirin and cyclodextrin. This is only be possible if the 
energy differences between the frontier orbitals of aspirin and –CD are reduced. 
The transitions and their obtained wavelengths from the UV spectrum of the complex are 
shown in Table 3. The transitions involve six occupied orbitals (343-348) considered here as 
nearly degenerated HOMO. They target to the same unoccupied orbital 349. We considered it as 
a unique LUMO.  
Table 3. The different transitions with their wavelengths observed in the computed UV spectrum 
of the ASA:–CD complex. 
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N° of the transition HOMO-LUMO Wavelength(nm) 
1 348-349 262 
2 347-349 259 
3 346-349 256 
4 345-349 253 
5 344-349 251 
6 343-349 249 
 
The HUMOs and LUMOs of the neutral complex are shown in Figure 13. 
 
 
Figure 13. The different orbitals HOMO and LUMO of the ASA:–CD  complex (neutral).  
We display in Figure 13, the LUMO (349) and the six aformentioned HOMO (343-348). The 
LUMO is located on the aspirin and the six HOMOs spread over the –CD. Thus, the six 
HOMO-LUMO transitions correspond to a donation from the –CD towards aspirin. This can be 
explained by the richness of the electronic density in cavity generated by the oxygen atoms of –
CD that will affect the electronic energy state of aspirin, which becomes close to those of –CD.  
3.2.6.2 Deprotonated complex 
The UV-visible computed spectrum of deprotonated aspirin (Figure 12 (b)) shows a band 
located at 280 nm. The absorption maximum of the spectrum of the inclusion complex is shifted 
to 232 nm, which is also an evidence of the formation of a new component. 
The transitions and their obtained energies from the UV-visible spectrum of the complex are 
shown in Table 4. The transitions involve three occupied orbitals (346-348) that we name as 
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nearly degenerated HOMOs. They target to three unoccupied orbital (349-351), that we name as 
as nearly degenerated LUMOs. 
 
Table 4: The different transitions with their wavelengths observed in the UV spectrum of the 
ASA
-
 :–CD complex. 
N° of the transition HOMO-LUMO Wavelength(nm) 
1 348-349 244 
2 348-350 241 
3 347-349 232 
4 347-350 226 
5 348-351 216 
6 346-349 213 
 
The HUMOs and LUMOs of the deprotonated complex as computed in the ground state are 
shown in Figure 14. As it can be seen, three LUMO orbitals are spread over aspirin (349, 350 
and 351). Whereas, for the HOMO orbitals, two orbitals (346 and 347) spread over the –CD  
and one (348) is over aspirin. Thus, the transitions from the HOMO (346 and 347) characterize 
the inclusion complex because these are the transitions from –CD towards aspirin. However, 
those from the HOMO (348) are related to the internal electronic transitions in aspirin itself. This 
can be explained by the effect of the partial inclusion. Indeed, an important part of aspirin 
remains outside of the cavity, retaining a part of its intrinsic properties. On the contrary, in the 
neutral complex, aspirin is completely embedded inside the cavity, and it loses entirely its 
intrinsic properties.  
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Figure 14. The different orbitals HOMO and LUMO of the ASA
-
: –CD complex.  
Conclusions 
Molecular dynamics and quantum mechanics applied to study the complexation process of 
aspirin and deprotonated aspirin with –CD give the neutral aspirin: –CD complex more 
favorable than the deprotonated one. In the neutral complex, the penetration occurs through the 
two entrances, and the more favorable orientation is that wherein the acetyl group penetrates first 
(orientation A). Moreover, the complexation process can be considered as irreversible. However, 
in the deprotonated complex, the penetration occurs through both of the wide and the narrow 
rims, and the complexation process is to be considered as reversible. The lowest energy 
minimum structures obtained by quantum mechanics show a deep inclusion in aspirin:–CD 
complex and partial in the deprotonated complex. The degree of penetration (deep or partial) is 
characterized by UV spectroscopy by determining the origin of the different electronic 
transitions.   
The NBO method describes a weak H-bond interactions in the neutral complex, and 
moderately strong in the deprotonated one; the AIM method confirms this and it also visualizes 
clearly the formation of these H-bonds as well. The hydrophobic/hydrophilic interactions are 
favorable for the neutral complex and unfavorable for the deprotonated one. 
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The shifts of the CO vibration of aspirin observed in calculated IR spectroscopy show the 
effect of the inclusion of aspirin inside the cavity and also they constitute the evidence of the 
formation of the inclusion complex in both cases. 
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